Galectin Therapeutics (GALT) Interest Expenses (2011 - 2026)

Galectin Therapeutics' Interest Expenses history runs 16 years deep, the most recent figure standing at $2.0 million for Q1 2026.

• On a quarterly basis, Interest Expenses rose 13.99% year-over-year to $2.0 million in Q1 2026; TTM through Mar 2026 was $7.6 million, a 994.36% increase from a year earlier, with the FY2025 full-year figure at $95.7 million, up 5.89% from the prior year.
• Interest Expenses rose to $2.0 million in Q1 2026 per GALT's latest filing, from $1.9 million in the prior quarter.
• Across five years, Interest Expenses topped out at $2.6 million in Q4 2023 and bottomed at -$3.8 million in Q4 2024.
• The 5-year median for Interest Expenses is $1.1 million (2024), against an average of $912941.2.
• Across the five-year window, Interest Expenses soared 655.35% in 2022 and slumped 244.62% in 2024, its largest moves.
• Year by year, Interest Expenses stood at $883000.0 in 2022, then soared by 198.75% to $2.6 million in 2023, then slumped by 244.62% to -$3.8 million in 2024, then soared by 150.83% to $1.9 million in 2025, then rose by 2.53% to $2.0 million in 2026.
• Per Business Quant, the three latest GALT Interest Expenses figures stand at $2.0 million (Q1 2026), $1.9 million (Q4 2025), and $1.8 million (Q3 2025).